IR contact details Carla Bretes Director Investor Relations and Business Development e: ir@moonlaketx.com Upcoming events More events are coming soon. View All Events View All Events + Corporate presentations Corporate presentation View All Presentations View All Presentations + Latest press releases Jan 08 2025 MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab Nov 13 2024 MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Nov 07 2024 MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update View All News View All Press Releases +
Jan 08 2025 MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
Nov 13 2024 MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
Nov 07 2024 MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update